54575-944 : Mesquite Pollen 1 g/20ml Percutaneous; Subcutaneous Injection, Solution


NDC54575-944
Labeler: Allergy Laboratories, Inc.
Product Type: Human Prescription Drug
Drug Name: Mesquite Pollen
Dosage Form: Percutaneous; Subcutaneous Injection, Solution
Application #: BLA101376
Rev. Date: 


NDC Package Codes:

  • 54575-944-02: 2 ML IN 1 VIAL, MULTI‑DOSE (54575‑944‑02)
  • 54575-944-10: 10 ML IN 1 VIAL, MULTI‑DOSE (54575‑944‑10)
  • 54575-944-30: 30 ML IN 1 VIAL, MULTI‑DOSE (54575‑944‑30)
  • 54575-944-50: 50 ML IN 1 VIAL, MULTI‑DOSE (54575‑944‑50)

Active Ingredients:

  • Prosopis Juliflora Pollen

Dosage Strength:

  • 1 g/20mL

Pharmaceutical Classes:

  • Non-Standardized Pollen Allergenic Extract [EPC]
  • Increased Histamine Release [PE]
  • Cell-mediated Immunity [PE]
  • Increased IgG Production [PE]
  • Pollen [CS]
  • Allergens [CS]

Related Products:

Based on records with the same trade name.
  • 49643-400 Mesquite Pollen 1 g/20ml Cutaneous; Intradermal; Subcutaneous Injection by Allermed Laboratories, Inc.

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 54575-944 QR Code

< Prev: 54575-943Next: 54575-945 >

Related Discussions:

pollen-eze hay fever tablets
can anyone please help, i had a severe reaction to pollen-eze hay fever tablets a few years ago, i want to know what the... 2 replies
Loss of voice due to pollen allergies
I have been on Betamax 875mg plus 125mg twice a day. How long will it take to cure the loss of voice due to allergies? #... 1 reply
rye pollen extract
Can I take finasteride and prostabrit [rye pollen extract] togther?...




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.